<DOC>
	<DOCNO>NCT01935635</DOCNO>
	<brief_summary>The purpose study investigate whether HB-Vac Activated-DCs Combined With Peg-IFN NAs efficacy Peg-IFN NAs alone treatment chronic hepatitis B patient</brief_summary>
	<brief_title>A Clinical Trial HB-Vac Activated-DCs Combined With Peg-IFN NAs CHB</brief_title>
	<detailed_description>The 450 patient meet entry criterion divide 6 group , clinical trial procedure divide 3 part , accord follow step : Part1 ( 0-12W ) : 1 . The research object group accord principle multicenter , randomize , open , parallel control clinical trial , 300 case cell therapy group ( 100 case PEG-IFN treatment , LdT treatment 100 case , ETV treatment 100 case ) , 150 case control group ( PEG-IFN therapy 50 case , LdT therapy 50 case , ETV treatment 50 case ) . Part2 ( 12-36W ) : 2 . Cell therapy group : enter HBsAg sensitize dendritic cell activate T cell ( HBsAg Pulse DCs-T , HPDCs-T ) immune therapy combine interferon ( IFN ) nucleoside analogues treatment ( NAs ) , infusion HPDC-T every 2 week 1 time , total 12 time . 3 . Control group : antiviral therapy use ( IFN NAs ) . Part3 ( 36-72W ) : 4 . The observation stage : discontinuation interferon treatment 48 week ; NAs case continue treatment NAs . HPDCs-T produced procedure : The first step : 1-7 day Monocytes isolated peripheral blood patient . The monocyte obtain incubated fresh serum-free AIM-V medium ( Gibco ) contain 800U/ml GM-CSF 400U/ml IL-4 ( Peprotech ) 5 day . After 5 day culture vitro , The DCs induce culture commercially available hepatitis B vaccine contain 10 ug HBsAg ( GSK ) 2 day . The second step : 8-14 day The hepatitis B vaccine sensitize DCs ( HPDCs ) ( first step ) sub-cultured patient 's PBMCs 7 day : HBsAg efficiently present PBMCs DCs , produce HBV specific CTLs HTLs ( HPDCs-T ) . The third step : 15 day The PBMCs ( second step ) contain enough HPDCs-T transfuse back patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>serum hepatitis B surface antigen ( HBsAg ) positive least 6 month ; HBV DNA loads≥ 104IU/ml ( Roche Cobas ) ; Containing IFN treatment : 2ULN ≤ ALT ≤ 10ULN TBil ≤ 2ULN ; Containing ETV/LdT treatment : 2ULN ≤ ALT TBil ≤ 5ULN ; All patient receive antiviral treatment immunotherapy last 6 month . superinfection coinfection hepatitis A , C , D , E , cytomegalovirus HIV , EpsteinBarr virus ; liver diseases alcoholic liver disease , druginduced hepatitis , Wilson disease autoimmune hepatitis ; ascites gastrointestinal bleeding peptic ulcer esophageal varix electronic gastroscope examination ; liver cirrhosis ; severe bacterial fungal infection ; history diabetes cardiac disease hypertension nephrosis ; pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CHB</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Dentritic cell</keyword>
	<keyword>Immune Therapy</keyword>
</DOC>